AGAntonello Ganau

Antonello Ganau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antonello Ganau has a total of 237 co-authors. Here are the top co-authors by number of shared publications:

  • Richard B. Devereux

    From the Division of Cardiology and the Hypertension Center, Department of Medicine, Cornell University Medical College, New York, NY (M.J.R., T.G.P., R.M.D.); Università di Firenze, Firenze, Italy (R.P.); and Università di Sassari, Sassari, Italy (A.G., P.S.S.).

    20 shared publications
  • Giovanni de Simone

    Federico II University

    19 shared publications
  • Mary J. Roman

    16 shared publications
  • Pier Sergio Saba

    Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy

    12 shared publications
  • Riccardo Pini

    Careggi University Hospital

    7 shared publications
  • John H. Laragh

    The Division of Cardiology, The New York Hospital–Cornell Medical Center, New York (G. de S., R.B.D., M.J.R., M.H.A., J.H.L.); Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy (G. de S., G.F.M.); and Institute of Clinical Medicine, University of Sassari (Italy) (A.G.).

    6 shared publications

Latest Publications

  • Echocardiographic heart ageing patterns predict cardiovascular and non-cardiovascular events and reflect biological age: the SardiNIA study

    by Antonello Ganau, Marco Orrù, Matteo Floris, Pier Sergio Saba, Federica Loi, Giuseppe D Sanna, Michele Marongiu, Lenuta Balaci, Niccolò Curreli, Liana A P Ferreli, et al.

    Aims: Age is a crucial risk factor for cardiovascular (CV) and non-CV diseases. As people age at different rates, the concept of biological age has been introduced as a personalized measure of functional deterioration. Associations of age with echocardiographic quantitative traits were analysed to assess different heart ageing rates and their ability to predict outcomes and reflect biological age. Methods and results: Associations of age with left ventricular mass, geometry, diastolic function, left atrial volume, and aortic root size were measured in 2614 healthy subjects. Based on the 95% two-sided tolerance intervals of each correlation, three discrete ageing trajectories were identified and categorized as ‘slow’, ‘normal’, and ‘accelerated’ heart ageing patterns. The primary endpoint included fatal and non-fatal CV events, and the secondary endpoint was a composite of CV and non-CV events and all-cause death. The phenotypic age of the heart (HeartPhAge) was estimated as a proxy of biological age. The slow ageing pattern was found in 8.7% of healthy participants, the normal pattern in 76.9%, and the accelerated pattern in 14.4%. Kaplan–Meier curves of the heart ageing patterns diverged significantly (P = 0.0001) for both primary and secondary endpoints, with the event rate being lowest in the slow, intermediate in the normal, and highest in the accelerated pattern. In the Cox proportional hazards model, heart ageing patterns predicted both primary (P = 0.01) and secondary (P = 0.03 to <0.0001) endpoints, independent of chronological age and risk factors. Compared with chronological age, HeartPhAge was 9 years younger in slow, 4 years older in accelerated (both P < 0.0001), and overlapping in normal ageing patterns. Conclusion: Standard Doppler echocardiography detects slow, normal, and accelerated heart ageing patterns. They predict CV and non-CV events, reflect biological age, and provide a new tool to calibrate prevention timing and intensity.


  • Open Access

    Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians

    by Angela Baralla, Elisabetta Sotgiu, Marta Deiana, Sara Pasella, Sara Pinna, Andrea Mannu, Elisabetta Canu, Giovanni Sotgiu, Antonello Ganau, Angelo Zinellu, et al.

    The role of Clusterin in attenuation of inflammation and reverse cholesterol transfer makes this molecule a potential candidate as a marker for cancer, cardiovascular disease, diabetes mellitus, and metabolic syndrome. In elderly subjects cardiovascular diseases represent the primary cause of death and different clinical studies have shown a positive correlation of these diseases with changes in the lipid pattern. This work aimed at evaluating the relationship between circulating clusterin and the biochemical parameters that characterize the lipid profile of a Sardinian population divided into five age groups including centenarians; the high frequency in Sardinia of these long-lived individuals gave us the opportunity to extend the range of the age groups to be analyzed to older ages and to better evaluate the changes in the lipid balance during ageing and its relationship with clusterin concentration in plasma. Our results showed that Clusterin concentration values of the youngest group were more similar with the centenarian’s group compared to the other age groups, and a positive correlation arises with LDL. Furthermore given the high prevalence of cardiovascular diseases in the population examined and the association of Clusterin with these pathologies we evaluated Clusterin concentration variation in two groups with or without cardiovascular diseases. In presence of cardiovascular disease, Clusterin is significantly related to the most atherogenic components of lipid profile (total cholesterol and LDL), especially in women, suggesting its potential role in modulating cardiovascular metabolic risk factors.


  • Ventricular–vascular coupling in hypertension

    by Pier Sergio Saba, Matteo Cameli, Giuseppina Casalnuovo, Marco M. Ciccone, Antonello Ganau, Maria Maiello, Pietro A. Modesti, Maria L. Muiesan, Salvatore Novo, Pasquale Palmiero, et al.

    The present review is addressed to analyse the complex interplay between left ventricle and arterial tree in hypertension. The different methodological approaches to the analysis of ventricular vascular coupling in the time and frequency domain are discussed. Moreover, the role of hypertension-related changes of arterial structure and function (stiffness and wave reflection) on arterial load and how ventricular-vascular coupling modulates the process of left ventricular adaptation to hypertension are analysed.The different interplay between vascular bed and left ventricle emerges as the pathophysiological basis for the development of the multiple patterns of ventricular structural adaptation in hypertension and provides a pathway for the interpretation of systolic and diastolic functional abnormalities observed in hypertensive patients. Targeting the therapeutic approach to improve ventricular-vascular coupling may have relevant impact on reversing left ventricular hypertrophy and improving systolic and diastolic dysfunction.


  • Serum free thyroxine levels are positively associated with arterial stiffness in the SardiNIA study

    by Alessandro P. Delitala, Marco Orrù, Fabiana Filigheddu, Maria Grazia Pilia, Giuseppe Delitala, Antonello Ganau, Pier Sergio Saba, Federica Decandia, Angelo Scuteri, Michele Marongiu, et al.

    Summary: Objective: Thyroid dysfunction may accelerate atherosclerosis. Aortic pulse wave velocity (PWV) is an early index of arterial stiffness and an important risk factor for cardiovascular disease and might therefore be linked to changes in thyroid activity. We investigated the relationship between thyroid function and carotid‐femoral PWV, as an index of arterial stiffness.Design: Cross‐sectional cohort study.Patients: Participants from the SardiNIA study. Those being treated for thyroid diseases were excluded, yielding a sample of 5875 aged 14–102.Measurements: Clinical parameters, blood tests including serum TSH and serum FT4, and carotid‐femoral PWV were measured.Results: After adjusting for confounders, a direct and linear association between FT4 and PWV was shown (multiple regression analysis). The model containing age, mean blood pressure, body mass index, heart rate, FT4, hypertension, diabetes and dyslipidaemia accounted for 55% of the variation in PWV.Conclusions: Like several other known risk factors, serum FT4 levels are associated with carotid‐femoral PWV, suggesting that high FT4 levels have a detrimental effect on aortic stiffness and may contribute to ageing process of the vascular system. This finding may help to understand the pathogenesis of cardiovascular disease and contribute to improve prevention therapy.


  • Hypertension and stable coronary artery disease

    by Roberto Pedrinelli, Piercarlo Ballo, Cesare Fiorentini, Maurizio Galderisi, Antonello Ganau, Giuseppe Germanò, Pasquale Innelli, Anna Paini, Stefano Perlini, Massimo Salvetti, et al.

    Systemic hypertension is highly prevalent in stable coronary artery disease, a pervasive comorbidity complicating the diagnostic performance and interpretation of non-invasive provocative tests in chest pain patients because of the ischaemic signals generated, despite normal or near normal coronary arteries, by hearts structurally readapted by long-term exposure to raised systemic blood pressure. Additional and unresolved problems posed by arterial hypertension in patients with stable coronary artery disease regard the benefits of antihypertensive treatment due to reports of irrelevant, if not detrimental, effect of blood pressure (BP) lowering in averting coronary relapses as well as the lack of association between BP levels and incident coronary events in survivors from acute myocardial infarction. Uncertainties extend to BP-independent cardioprotective effects of antihypertensive drugs, although the efficacy of renin-angiotensin system blockers in the long-term prevention of cardiovascular events in stable coronary artery disease patients has been shown by several studies, particularly when combined with amlodipine, a dihydropiridine calcium channel blocker. In contrast, the long-term effect of beta-blockers, the antihypertensive class most used in that clinical category, is not supported by strong evidence except that generated in patients with systolic dysfunction and early postmyocardial infarction recovery periods.


  • Incidental diagnosis of cor triatriatum and ventricular septal defect in the elderly

    by Giuseppe Damiano Sanna, Pier Sergio Saba, Antonella Canu, Federica Decandia, Giovanni Di Girolamo, Antonello Ganau


  • Primary motor cortex hyperexcitability in Fabry’s disease

    by Enzo Ortu, Laura Fancellu, GianFranco Sau, Paolo Falchi, Sebastiano Traccis, Giovanni Mario Pes, Antonello Ganau, GianPietro Sechi


  • Indexing cardiac parameters in echocardiographic practice: Do estimates depend on how weight and height have been assessed? A study on left atrial dilatation

    by Cesare Cuspidi, Francesca Negri, Maria Lorenza Muiesan, Anna Maria Grandi, Laura Lonati, Antonello Ganau, Daniela Degli Esposti, Alberto Milan, Carla Sala, Rita Facchetti, et al.


  • Self-Reported Weight and Height: Implications for Left Ventricular Hypertrophy Detection. An Italian Multi-Center Study

    by Cesare Cuspidi, Francesca Negri, Valentina Giudici, Maria Lorenza Muiesan, Anna Maria Grandi, Antonello Ganau, Laura Lonati, Daniela Degli Esposti, Anna Capra, Alberto Milan, et al.

    We examined the difference between self-reported and measured body size values and their impact on detection of left ventricular hypertrophy (LVH) by echocardiographic LV mass indexation. A total of 1963 subjects referred by their practitioners for routine echocardiographic examination to nine outpatient echocardiographic laboratories across Italy were included in the study. Left ventricular hypertrophy was defined according to two gender- specific criteria as: A) Left ventricular mass (LVM) index ≥49 g/h(2.7) in men and ≥45 g/h(2.7) in women; B) LVM index ≥125 g/m(2) in men and ≥110 g/m(2) in women. Prevalence of LVH was calculated by indexing LVM to both self-reported and measured anthropometric values. In the whole population, LVH tended to be underestimated by self-reported values by 5.4% according to criterion A (48.5% vs. 53.9%, p < 0.001) and by 1.2% according to criterion B (29.6% vs. 30.8%, p < 0.01); similar findings were observed in the hypertensive subgroup encompassing one-half of the sample. Underestimation of LVH was more pronounced in older patients than in younger patients: 8.6% vs. 3.2% (p < 0.001) by criterion A, 3.1% vs. 0.1% (p < 0.001) by criterion B, in women than in men (8.6% vs. 3.3% (p < 0.001) by criterion A and 1.8% vs. 0.5% (p < 0.01) by criterion B. In a sample of outpatients attending echocardiographic laboratories, LVH is misclassified when left ventricular mass is normalized to self-reported weight and height. The error is related to the clinical characteristics of patients and is more pronounced when LVM is normalized to height(2.7).